

Timing and order of pathological events in Alzheimer's disease: focus on the trajectory of the awareness of cognitive decline

Federica Cacciamani, Arnaud Valladier, Etienne Maheux, Igor Koval, Stanley Durrleman, Stéphane Epelbaum

▶ To cite this version:

Federica Cacciamani, Arnaud Valladier, Etienne Maheux, Igor Koval, Stanley Durrleman, et al.. Timing and order of pathological events in Alzheimer's disease: focus on the trajectory of the awareness of cognitive decline. AD/PD 2021 - 15thInternational Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, Mar 2021, Barcelone / Virtual, Spain. hal-03030182

HAL Id: hal-03030182

https://hal.science/hal-03030182

Submitted on 18 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Timing and order of pathological events in Alzheimer's disease: focus on the trajectory of the awareness of cognitive decline

Federica Cacciamani¹, Arnaud Valladier¹, Etienne Maheux¹, Igor Koval¹, Stanley Durrleman¹, Stéphane Epelbaum^{1,2}

¹ ARAMIS Lab, Institut du Cerveau (ICM) – Paris Brain Institute, (CNRS, Sorbonne University, Inria, Inserm), Pitié-Salpêtrière Hospital, Paris, France

15th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD™ 2021

Objectives

We built an Alzheimer's disease (AD) Course Map depicting the timing and order of the pathological events occurring during AD progression, with a particular focus on the evolution of the awareness of cognitive decline (ACD).

Methods

We included 373 ADNI participants with positive markers of amyloid and tau (A+T+), and 145 A-T-cognitively-normal controls.

The AD Course Map was built by including measures of global cognition (MMSE), episodic memory (RAVLT), autonomy (FAQ), self- and informant-reported ratings of cognitive functioning (E-Cog), brain metabolism, hippocampal volume. An Awareness of Cognitive Decline Index (ACDI) was computed as the subject-informant discrepancy in the E-Cog score. All measures were normalized between 0 (normal) and 1 (abnormal). We used a non-linear Bayesian mixed-effects model in the Leaspy software (https://gitlab.com/icm-institute/aramislab/leaspy/).

Results

Our model identified the following temporal sequence of events in AD (see Figure): the episodic memory was the first measure to become abnormal in A+T+ subjects (i.e. different from controls), followed by autonomy, study-partner's E-Cog score, brain metabolism and MMSE, hippocampal volume, and finally subject's E-Cog score (this letter occurring around 3 years after the diagnosis of dementia).

The ACDI had a non-linear evolution: the subject initially experiences cognitive complaints but his/her ACD soon decreases, eventually constituting a clear anosognosia.

Conclusions

The study of ACD in AD is a piece of the larger understanding of the pre-dementia phases. The presence of an informant is useful to identify the first signs of the disease and anticipate the diagnosis.

² Institute of Memory and Alzheimer's Disease (IM2A), Centre of excellence of neurodegenerative disease (CoEN), ICM, CIC Neurosciences, AP-HP, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France

